BioCentury
ARTICLE | Product Development

COVID-19 vaccines that could report Phase III data before Moderna, Pfizer-BioNTech products become broadly available 

With EUAs coming soon for two COVID-19 vaccines, it could soon get harder to convince patients to enroll in trials of others. 

November 19, 2020 2:05 AM UTC

Strong efficacy data from the two leading COVID-19 vaccines suggest the window for testing additional vaccine candidates in the U.S. could soon start to close. Of the more than 200 vaccines in development for COVID-19, at least seven have a chance of gathering pivotal data before the front-runners become broadly available, making recruitment difficult.

With protection rates of 95% and two-month safety data in or imminent, Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said in a briefing Wednesday that he expects emergency use authorizations (EUAs) for BNT162b2 from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) and mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) to come as early as the middle of December...



Access The Full Article